192 related articles for article (PubMed ID: 15329529)
1. Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia.
Manfredi R; Calza L; Chiodo F
Infez Med; 2004 Mar; 12(1):51-9. PubMed ID: 15329529
[TBL] [Abstract][Full Text] [Related]
2. Gynecomastia associated with highly active antiretroviral therapy.
Manfredi R; Calza L; Chiodo F
Ann Pharmacother; 2001 Apr; 35(4):438-9. PubMed ID: 11302408
[TBL] [Abstract][Full Text] [Related]
3. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2004 Jan; 35(1):99-102. PubMed ID: 14707802
[No Abstract] [Full Text] [Related]
4. [Experience at a branch center of the National HIV Protease Inhibitor Registry].
Franco A; Aprea L; Geraci A; Manzillo E; Pizzella T; Simioli F; Mongirulli A; Izzo CM
Infez Med; 2001 Sep; 9(3):170-5. PubMed ID: 12087219
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
[TBL] [Abstract][Full Text] [Related]
6. Efavirenz-associated gynecomastia: report of five cases and review of the literature.
Jover F; Cuadrado JM; Roig P; Rodríguez M; Andreu L; Merino J
Breast J; 2004; 10(3):244-6. PubMed ID: 15125753
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.
Tomazic J; Silic A; Karner P; Vidmar L; Maticic M; Poljak M; Ihan A; Janez A
Wien Klin Wochenschr; 2004 Nov; 116(21-22):755-9. PubMed ID: 15628647
[TBL] [Abstract][Full Text] [Related]
8. Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy.
Deonarain J; Ramdial PK; Singh B
Int J Surg Pathol; 2008 Apr; 16(2):171-5. PubMed ID: 18417674
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
10. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
11. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Sension M; Deckx H
AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
[TBL] [Abstract][Full Text] [Related]
12. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
14. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
Introcaso CE; Hines JM; Kovarik CL
J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
[TBL] [Abstract][Full Text] [Related]
16. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.
Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A;
BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838
[TBL] [Abstract][Full Text] [Related]
18. Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.
Aquilina C; Viraben R
Int J STD AIDS; 2001 Jul; 12(7):481-2. PubMed ID: 11394987
[TBL] [Abstract][Full Text] [Related]
19. What should we know about metabolic syndrome and lipodystrophy in AIDS?
Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
[TBL] [Abstract][Full Text] [Related]
20. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
Caso JA; Prieto Jde M; Casas E; Sanz J
AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
